Mirabegron

Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

 

It is commercialised in Europe by Astellas pharma as Betmiga.

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 634559

More

Follow us

© 2015 created with Wix.com